IGF-IRβ Inhibitors
Common IGF-IRβ Inhibitors include, but are not limited to Linsitinib CAS 867160-71-2, AG 1024 CAS 65678-07-1, NVP-ADW742 CAS 475488-23-4, IGF-1R Inhibitor, PPP CAS 477-47-4 and HNMPA-(AM)3 CAS 120944-03-8.
The Insulin-like Growth Factor-1 Receptor (IGF-IR) is a transmembrane receptor tyrosine kinase that is pivotal in mediating the biological effects of the Insulin-like Growth Factor (IGF) family, which includes IGF-I and IGF-II. Structurally, the IGF-IR is a heterotetrameric protein composed of two extracellular α-subunits and two transmembrane β-subunits. The β-subunit (IGF-IRβ) contains the intrinsic tyrosine kinase activity, which becomes autophosphorylated upon ligand binding. This autophosphorylation event subsequently initiates a cascade of downstream signaling pathways, particularly the PI3K/AKT and the MAPK/ERK pathways, which are crucial in regulating cell survival, proliferation, differentiation, and metabolism.
IGF-IRβ inhibitors are specialized molecules designed to target the kinase activity of the IGF-IRβ subunit, thereby attenuating the downstream signaling events initiated by the receptor. These inhibitors commonly function by binding to the ATP-binding pocket of the kinase domain, hindering its phosphorylation and consequent activation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Linsitinib | 867160-71-2 | sc-396762 sc-396762A | 5 mg 10 mg | $146.00 $265.00 | 1 | |
Linsitinib is a dual inhibitor of IGF-1R and the insulin receptor. By inhibiting IGF-1R kinase activity, it can reduce downstream signaling and possibly down-regulate IGF-IRβ expression. | ||||||
BMS-754807 | 1001350-96-4 | sc-507396 | 5 mg | $304.00 | ||
BMS-754807 is an ATP-competitive inhibitor of IGF-1R which can suppress its kinase activity, potentially leading to reduced expression and function of IGF-IRβ. | ||||||
AG 1024 | 65678-07-1 | sc-205907 | 1 mg | $107.00 | 22 | |
AG-1024 is a tyrosine kinase inhibitor that inhibits IGF-1R autophosphorylation, which may reduce IGF-IRβ expression. | ||||||
NVP-AEW541 | 475489-16-8 | sc-507395 | 5 mg | $285.00 | ||
NVP-AEW541 selectively inhibits IGF-1R kinase activity, which could result in the down-regulation of IGF-IRβ expression. | ||||||
NVP-ADW742 | 475488-23-4 | sc-391129 sc-391129A | 5 mg 10 mg | $255.00 $480.00 | ||
NVP-ADW742 is an IGF-1R inhibitor, which by suppressing the kinase activity, might lead to reduced IGF-IRβ expression. | ||||||
GSK1904529A | 1089283-49-7 | sc-507398 | 10 mg | $321.00 | ||
GSK1904529A is a potent inhibitor of IGF-1R kinase activity, potentially suppressing IGF-IRβ expression. | ||||||
IGF-1R Inhibitor, PPP | 477-47-4 | sc-204008A sc-204008 sc-204008B | 1 mg 10 mg 100 mg | $138.00 $203.00 $895.00 | 63 | |
PPP is a non-ATP competitive inhibitor of IGF-1R, which might lead to a decrease in IGF-IRβ expression. | ||||||
HNMPA-(AM)3 | 120944-03-8 | sc-221730 | 5 mg | $190.00 | 12 | |
HNMPA(AM)3 inhibits IGF-1R autophosphorylation, potentially leading to down-regulation of IGF-IRβ. | ||||||